“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy

Bassam Janji; Salem Chouaib

doi:10.1080/2162402X.2021.1968611

“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy

Bassam Janji^*, Salem Chouaib

^*Corresponding author for this work

Tumor Immunotherapy and Microenvironment

Research output: Contribution to journal › Article › Research › peer-review

4 Citations (Scopus)

Abstract

We recently reported that inhibiting Hypoxia-inducible Factor-1α (Hif1a) transcriptional activity improves melanoma immunotherapy by driving immune cells into the tumor microenvironment (TME). This Author’s View provides additional perspectives on how hypoxia inhibitors combined with immunotherapy can be used as innovative approaches to improve the therapeutic benefit of melanoma patients.

Original language	English
Article number	1968611
Pages (from-to)	1968611
Journal	OncoImmunology
Volume	10
Issue number	1
DOIs	https://doi.org/10.1080/2162402X.2021.1968611
Publication status	Published - 7 Sept 2021

Keywords

CCL5/Rantes
CD8 T-lymphocytes
Hypoxia
NK cells
anti-PD-1/PD-L1
cancer immunotherapy
chemokines
cold/hot tumors
hypoxia-inducible factor
immune landscape
melanoma

Access to Document

10.1080/2162402X.2021.1968611Licence: CC BY-NC

Cite this

@article{8014c6b7367b490eb78b9d20e385393e,

title = "“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy",

abstract = "We recently reported that inhibiting Hypoxia-inducible Factor-1α (Hif1a) transcriptional activity improves melanoma immunotherapy by driving immune cells into the tumor microenvironment (TME). This Author{\textquoteright}s View provides additional perspectives on how hypoxia inhibitors combined with immunotherapy can be used as innovative approaches to improve the therapeutic benefit of melanoma patients.",

keywords = "CCL5/Rantes, CD8 T-lymphocytes, Hypoxia, NK cells, anti-PD-1/PD-L1, cancer immunotherapy, chemokines, cold/hot tumors, hypoxia-inducible factor, immune landscape, melanoma",

author = "Bassam Janji and Salem Chouaib",

note = "Funding Information: This work was supported by grants from Luxembourg National Research Fund (BRIDGES2020/BM/15412275), ROCHE pharma, and Sheik Hamdan Bin Rashid Al Maktoum Foundation, United Arab Emirates Publisher Copyright: {\textcopyright} 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2021",

month = sep,

day = "7",

doi = "10.1080/2162402X.2021.1968611",

language = "English",

volume = "10",

pages = "1968611",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - “Suffocating” tumors by blocking adaptation to hypoxia

T2 - a new headway in melanoma immunotherapy

AU - Janji, Bassam

AU - Chouaib, Salem

N1 - Funding Information: This work was supported by grants from Luxembourg National Research Fund (BRIDGES2020/BM/15412275), ROCHE pharma, and Sheik Hamdan Bin Rashid Al Maktoum Foundation, United Arab Emirates Publisher Copyright: © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

PY - 2021/9/7

Y1 - 2021/9/7

N2 - We recently reported that inhibiting Hypoxia-inducible Factor-1α (Hif1a) transcriptional activity improves melanoma immunotherapy by driving immune cells into the tumor microenvironment (TME). This Author’s View provides additional perspectives on how hypoxia inhibitors combined with immunotherapy can be used as innovative approaches to improve the therapeutic benefit of melanoma patients.

AB - We recently reported that inhibiting Hypoxia-inducible Factor-1α (Hif1a) transcriptional activity improves melanoma immunotherapy by driving immune cells into the tumor microenvironment (TME). This Author’s View provides additional perspectives on how hypoxia inhibitors combined with immunotherapy can be used as innovative approaches to improve the therapeutic benefit of melanoma patients.

KW - CCL5/Rantes

KW - CD8 T-lymphocytes

KW - Hypoxia

KW - NK cells

KW - anti-PD-1/PD-L1

KW - cancer immunotherapy

KW - chemokines

KW - cold/hot tumors

KW - hypoxia-inducible factor

KW - immune landscape

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=85114463793&partnerID=8YFLogxK

UR - https://www.ncbi.nlm.nih.gov/pubmed/34527430

U2 - 10.1080/2162402X.2021.1968611

DO - 10.1080/2162402X.2021.1968611

M3 - Article

C2 - 34527430

AN - SCOPUS:85114463793

SN - 2162-4011

VL - 10

SP - 1968611

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 1968611

ER -

“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this